Avantor, Inc. (NYSE:AVTR) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its holdings in Avantor, Inc. (NYSE:AVTR) by 403.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 133,515 shares of the company’s stock after acquiring an additional 106,992 shares during the period. Assenagon Asset Management S.A.’s holdings in Avantor were worth $2,831,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc boosted its position in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares during the last quarter. Gladius Capital Management LP acquired a new position in Avantor in the 4th quarter valued at about $42,000. Montag A & Associates Inc. purchased a new stake in shares of Avantor in the 4th quarter valued at approximately $43,000. TFO Wealth Partners LLC increased its holdings in shares of Avantor by 203,100.0% during the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after buying an additional 2,031 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new stake in shares of Avantor during the 4th quarter valued at approximately $47,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $30.00 to $23.00 in a research report on Wednesday, July 10th. Barclays increased their price target on Avantor from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Stifel Nicolaus boosted their price objective on shares of Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. Morgan Stanley increased their target price on shares of Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Finally, TD Cowen boosted their price target on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.21.

Avantor Stock Up 0.7 %

Avantor stock opened at $25.58 on Wednesday. The firm has a market capitalization of $17.38 billion, a P/E ratio of 65.59, a P/E/G ratio of 2.71 and a beta of 1.32. The company has a current ratio of 1.59, a quick ratio of 1.05 and a debt-to-equity ratio of 0.89. Avantor, Inc. has a twelve month low of $16.63 and a twelve month high of $28.00. The stock’s fifty day simple moving average is $22.90 and its 200-day simple moving average is $24.03.

Avantor (NYSE:AVTR) last released its earnings results on Friday, July 26th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. The firm had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Avantor had a return on equity of 12.40% and a net margin of 5.28%. As a group, equities analysts expect that Avantor, Inc. will post 1.01 earnings per share for the current fiscal year.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.